Single stranded的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列地圖、推薦、景點和餐廳等資訊懶人包

Virus-Like Particles: A Comprehensive Guide

為了解決Single stranded的問題，作者Pumpens, Paul,Pushko, Peter 這樣論述：

Paul Pumpens, PhD, graduated from the Chemical Department of the University of Latvia in 1970 and earned his PhD in molecular biology from the Latvian Academy of Sciences, Riga and DSc from the Institute of Molecular Biology of the USSR Academy of Sciences, Moscow, USSR. Dr. Pumpens started his rese

arch career as a research fellow at the Institute of Organic Synthesis, where he conducted research from 1973 to 1989. He served as head of the Laboratory of Protein Engineering at the Institute of Organic Synthesis (1989-1990), as head of the Department of Protein Engineering at the Institute of Mo

lecular Biology of the Latvian Academy of Sciences (since 1993, the Biomedical Research and Study Centre) in Riga (1990-2002), and as scientific director of the Biomedical Research and Study Centre (2002-2014). He served as a professor of the Biological Department of the University of Latvia from 19

99 until 2013. Dr. Pumpens pioneered genetic engineering research in Latvia. He was one of the first in the world to perform successful cloning of the hepatitis B virus genome and the expression of hepatitis B virus genes in bacterial cells. His major scientific interests are in designing novel reco

mbinant vaccines and diagnostic reagents and development of tools for gene therapy based on virus-like particles. Dr. Pumpens is an author of more than 300 scientific papers and issues or pending patents. He has edited, together with Dr. Yury E. Khudyakov, the Taylor & Francis book Viral Nanotechnol

ogy (2015) and authored the Taylor & Francis book Single-stranded RNA phages: From molecular biology to nanotechnology (2020). Dr. Peter Pushko graduated in 1984 from the University of Latvia, Riga, USSR and received his doctorate degree in Molecular Biology in 1990 from the University of Tartu (Tar

tu, Estonia) under mentorship of Dr. Paul Pumpens. He worked at the Institute of Molecular Biology (Riga, Latvia) on chimeric virus-like particles derived from bacteriophage fr and from hepatitis B virus. He completed postdoctoral studies at the Institute of Virology (Berlin, Germany), State Bacteri

ological Laboratory (Stockholm, Sweden) and Imperial Cancer Research Fund (Department of Pathology, University of Cambridge, U.K.) From 1994 to 2000, Dr. Pushko worked at the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID, Fort Detrick, Maryland, USA) as the National Research

Council fellow. During this period, he developed RNA vector system from Venezuelan equine encephalitis (VEE) virus replicon and prepared experimental vaccines against Ebola, Marburg, and Lassa hemorrhagic fever viruses. In 2000-2010, Dr. Pushko worked at Novavax, Inc., (Rockville, MD), where he dev

eloped recombinant virus-like particles (VLPs) as vaccines against influenza. Since 2010, Dr. Pushko serves as the President and Chief Scientific Officer at Medigen Inc. (Frederick, Maryland), a biopharmaceutical company developing innovative vaccines for emerging infectious diseases and cancer. His

scientific interests include vaccine development for emerging viruses, such as pandemic influenza, alpha-, arena-, and flaviviruses. He developed several novel vaccine technologies including VEE replicon vector, influenza VLPs, and DNA-launched live-attenuated vaccines. Dr. Pushko is the author of

over 50 patents and 70 publications.

Single stranded進入發燒排行的影片

結合準確而高效的化學相似物搜尋引擎以及接觸分佈擬合法來挑選能調控新冠病毒框架轉移效率的FDA老藥以阻殺病毒

為了解決Single stranded的問題，作者艾哈邁德 這樣論述：

截至論文撰寫之時，世界上超過 50% 的人口已在一年內第三次接種疫苗，以抵禦由冠狀病毒（SARS-CoV2）所引起的百年以來最大的流行病。與每季均能逃避疫苗識別而不斷突變的棘蛋白相比，-1 程序性核醣體移碼 (-1 PRF) 與觸發此PRF機制的 mRNA 假結 (PK)在演化上相對保守許多，包含冠狀病毒在內的病毒屬。因此，科學家們非常感興趣的是可以開發調節PRF的藥物來干擾病毒蛋白的轉譯，進而干擾病毒的複製。儘管科學家已了解PK 的平衡結構及其在核醣體上的位置，但人們仍不清楚 PK 如何的誘導 PRF 產生以及藥物應被設計結合在 PK 中的什麼位置才能增強或減少病毒的移碼效率（FE%）。在

本論文中，我們展示了通過整合小分子對接、分子動力學（MD）模擬和少量藥物的體外篩選，來實現抗 PK 藥物的設計。我們開發了一種新方法：接觸分佈匹配，以有效及省時地找到讓FE%上升或下降的調節劑。這些調節劑是從 2000 多種 FDA 批准的藥物庫中挑選出來的，所以可以讓醫師有機會來off-label使用。接觸分佈由分析一個藥物前十名與SARS-CoV2 PK結合的低能量構型而來，此PK的結構是由冷凍電鏡解析出後，以分子動力學模擬(MD simulations)來鬆弛 (relax) 平衡。通過小分子對接的概率分佈匹配及根據雙螢光素酶測定 (DLA) 所確定現有 FE% 調節劑的證據，我們有效地

擴大了可以篩選的藥物數量。為了支持此平台，我們也開發了化學相似性搜索引擎 SmChem，找出少數可有效調控FE%的 FDA 藥物（老藥新用），並以生化和病毒抑制試驗中來驗證。我們使用此新平台僅對十種藥物進行了篩選，就發現了兩種新的 FE% 變化調節劑，並且該藥在化學結構上不同於已知的調節劑。通過使用光鑷 (OT) 在有或無FE% 調節劑的情況下進一步測試 PK 的機械穩定性和解旋力(unfolding forces)中間體的數量，我們對 PK 的構象可塑性和 PRF 效率之間的相關性提供了新的見解，主要在於FE%增加劑比FE%抑制劑更能減少解旋力中間體的生成但解旋力卻變化不大。這些結果對我們如

何能合理地設計藥物以靶向有翻譯調節功能的 RNA結構提供了一個明確的證據，並提供了一種進化上保守且及時的途徑來使用FDA 已核准的藥物以應對病毒感染。

The Meeting Point

為了解決Single stranded的問題，作者Lara, Olivia 這樣論述：

＂What if the Lift driver who finds your cheating boyfriend’s phone holds the directions to true love? ’Who are you and why do you have my boyfriend’s phone?’ ’He left it in my car. You must be the blonde in the red dress? I’m the Lift driver who dropped you two off earlier.’ And with these words,

the life of the brunette and t-shirt wearing Maya Maas is turned upside down. Having planned to surprise her boyfriend, she finds herself single and stranded in an unknown city on her birthday. So when the mystery driver rescues Maya with the suggestion that she cheers herself up at a nearby beach

town, she jumps at the chance to get things back on track. She wasn’t expecting a personalised itinerary or the easy companionship that comes from opening up to a stranger via text, let alone the possibility it might grow into something more...＂--Provided by publisher.

運用房水蛋白質體學於白內障及黃斑病變之眼睛疾病探討

為了解決Single stranded的問題，作者章瑋真 這樣論述：

白內障與原發性黃斑皺褶是很常見導致視力受損的共病疾病，在臨床上很常遇見病患白內障術後視力仍未改善的原因是因為有黃斑皺褶的影響，探討此二種疾病的房水蛋白質組成，有助於了解分別的病理致病機轉，藉此可能可以提供臨床上白內障疾病及原發性黃斑皺褶的預測及追蹤治療。原發性黃斑皺褶是位於黃斑部玻璃體與視網膜交界處的病理性纖維細胞病變，目前其可能的致病機制仍不清楚，藉由眼內房水蛋白質組成的變化，可能可以瞭解原發性黃斑部皺褶相關的分子變化；而白內障則是另一種常見的可致失明的眼部疾病，在蛋白質組成中發現可能導致白內障的疾病關鍵因子，將有助於更進一步了解白內障形成過程中的分子機轉。我們的目標是希望透過分析房水中蛋

白質體分析去發現原發性黃斑皺褶的病理生理機轉，並從不同白內障風險因子暴露的組別中，蛋白質體的分析去找尋導致白內障的潛在的分子機轉。首先，為了研究原發性黃斑皺褶和對照組的眼房水蛋白質組成，我們收集了來自10名原發性黃斑皺褶患者和 10名年齡匹配的對照組的樣本。然後，為了比較具有不同白內障致病危險因子（如糖尿病和吸煙）的白內障患者和無風險暴露的白內障對照組患者的房水蛋白表現有無差異，我們使用了無標記超高效液相色譜串聯質譜分析法，共收案了有8名糖尿病和吸煙患者（具有雙重風險因素）、5名糖尿病患者和 5 名吸煙患者（均具有單一風險因素）和10名年齡匹配的白內障對照患者（非風險暴露）入組。在原發性黃斑皺

褶和對照組之間，有 8 種蛋白質有差異表達。其中六種蛋白質被發現增加表現，兩種減少表現。基因本體論(Gene Ontology)分析表現出原發性黃斑皺褶與免疫功能有相互作用、與細胞增生和細胞外基質重塑等多個生物學過程密切相關。此外，多種蛋白質，包括Lumican蛋白、細胞週期蛋白依賴性激酶 13(cyclin-dependent kinase 13) 和膠原蛋白 alpha-3(VI)鍊(collagen alpha-3(VI) chain)皆與中央視網膜厚度相關，表示這些蛋白可能參與原發性黃斑皺褶的致病過程。眼房水中的Lumican表現亮在二組間有顯著差異也藉由酶聯免疫吸附試驗 (ELISA

) 得到證實。在探討白內障風險因子影響的研究中，共找到了136種房水蛋白，其中只有alpha-2-HS- glycoprotein被認為與不同風險暴露下的三組有顯著相關，因為它在這三組中存在差異表達，並且隨著風險的增加而表現量增加，我們也使用了ELISA確認糖尿病和對照樣品之間以及吸煙和對照組之間的房水alpha-2-HS- glycoprotein蛋白有顯著的變化。Lumican可能可以成為預測原發性黃斑皺褶產生和監測其進展的潛在房水生物標記物，而Alpha-2-HS- glycoprotein，亦稱為fetuin-a，可能是與糖尿病和吸煙這些白內障的致病風險因子相關的房水生物標記物。蛋白質

組學是研究人類房水組成很有用的工具，它為原發性黃斑皺褶和白內障疾病提供了許多有意義的線索可供進一步研究及探討。